Search Results
Aug 27, 2026, 08:00 ET PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
More news about: PTC Therapeutics, Inc.
Aug 24, 2026, 08:00 ET PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors
More news about: PTC Therapeutics, Inc.
Aug 12, 2026, 16:01 ET PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease
More news about: PTC Therapeutics, Inc.
Jul 30, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
–WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026. "Our teams delivered another strong quarter
More news about: PTC Therapeutics, Inc.
Jul 23, 2026, 07:00 ET Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
was also a Visiting Professor at Yale-NUS College Singapore.He currently serves as Chairman and director of PTC Therapeutics, Inc. (Nasdaq: PTCT), a publicly traded biotechnology company focused on treatments for rare genetic disorders. He is also Chairman and a director of Berryville Holdings,
More news about: Hamilton Lane
Jul 16, 2026, 08:00 ET PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the
More news about: PTC Therapeutics, Inc.
Jun 17, 2026, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock
More news about: PTC Therapeutics, Inc.
Jun 15, 2026, 23:14 ET PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
–WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement
More news about: PTC Therapeutics, Inc.
Jun 15, 2026, 07:00 ET PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
–WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior
More news about: PTC Therapeutics, Inc.
May 07, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
–WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026. "We are off to a strong start to 2026 with
More news about: PTC Therapeutics, Inc.
May 04, 2026, 08:00 ET PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 16:05 ET PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
- WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension
More news about: PTC Therapeutics, Inc.
Apr 22, 2026, 08:00 ET PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the
More news about: PTC Therapeutics, Inc.
Apr 17, 2026, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock
More news about: PTC Therapeutics, Inc.
Mar 25, 2026, 08:30 ET PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with
More news about: PTC Therapeutics, Inc.
Mar 13, 2026, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock
More news about: PTC Therapeutics, Inc.
Feb 23, 2026, 08:00 ET PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
More news about: PTC Therapeutics, Inc.
Feb 19, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
–WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025. "We delivered another
More news about: PTC Therapeutics, Inc.
Feb 18, 2026, 17:31 ET Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
NGGT, Jnana Therapeutics, BioMarin (NASDAQ: BMRN), PTC Therapeutics (NASDAQ: PTCT), and othersKey Phenylketonuria Therapies
More news about: DelveInsight Business Research, LLP
Feb 12, 2026, 17:00 ET PTC Therapeutics Provides Regulatory Update on Translarna™
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation
More news about: PTC Therapeutics, Inc.
Feb 05, 2026, 08:00 ET PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an
More news about: PTC Therapeutics, Inc.
Jan 12, 2026, 08:30 ET PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
–WARREN, N.J., Jan. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these
More news about: PTC Therapeutics, Inc.
Jan 08, 2026, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of
More news about: PTC Therapeutics, Inc.
Dec 22, 2025, 23:29 ET A PTC Therapeutics anuncia a aprovação do Sephience™ (sepiapterina) para o tratamento de crianças e adultos que vivem com fenilcetonúria (PKU) no Japão
WARREN, Nova Jersey, 23 de dezembro de 2025 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o Sephience™ (sepiapterina) foi aprovado pelo Ministério da Saúde, Trabalho e Bem-Estar (MHLW) do Japão para o tratamento de crianças
More news about: PTC Therapeutics, Inc.